Ethical implications of communicating molecular test results to families with hereditary predisposition to cancer;Implicaţii Eticeîn Comunicarea Rezultatelor Testelor Moleculare Cǎtre Familiile cu Predispoziţie Ereditarǎ la Cancer

Revista Romana de Bioetica

Volumn 8, Issue 4, 2010, Pages 156-165

  Negurǎ, Anca ^a   Matei, Mioara ^b   Negurǎ, Lucian ^b   Carasevici, Eugen ^b   Uhrhammer, Nancy ^c   Bignon, Yves Jean ^c   Azoicǎi, Doina ^b  

^a ALEXANDRU IOAN CUZA UNIVERSITY OF IASI   (Romania)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c CENTRE JEAN PERRIN   (France)

Author keywords

Genetic counseling; Hereditary cancer; Intra family communication; Molecular test; Responsibility

Indexed keywords

EID: 83455214149     PISSN: 15835170     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L. et al., Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet, 72(5):1117-1130, 2003
2. Bell D., Bennett B., Genetic secrets and the family. Med Law Rev, 9:130-161, 2001
3. Bermejo J.L., Hemminiki K., Risks of cancer and families. J Natl Cancer Inst., 98(8):563-564, 2006
4. Bradbury A.R., Dignam J.J., Ibe C.N., Auh S.L., Hlubocky F.J., Cummings S.A. et al., How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. Journal of Clinical Oncology, 25(24):3705-3711, 2007
5. Breast Information Core (BIC) database (http://research.nhgri.nih.gov/bic/).
6. Cappelli M., Verma S., Korneluk Y., Hunter A., Tomiak E., Allanson J. et al., Psychological and genetic counseling implications for adolescent daughters of mothers with breast cancer. Clin Genet, 67:481-491, 2005
7. Chetrit A., Hirsh-Yechezkel G., Ben-David Y., Lubin F., Friedman E., Sadetzki S., Effect of BRCA1/2 Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer. J clin oncol, 26(1):9-10, 2008
8. Dalla Palma L., Tomorrow's radiologist: what future? Radiol Med, 111(5), 621-633, 2006
9. Dickens B.M., Pei N., Taylor K.M., Legal and ethical issues in genetic testing and counseling for susceptibility to breast, ovarian and colon cancer. CMAJ, 154(6):813-818, 1996
10. Easton D.F., Hopper J.L., Thomas D.C., Antoniou A., Pharoah P.D.P., Whittemore A., Haile R.W., Breast cancer risks for BRCA1/2 carriers. Science, 306:2187-2188, 2004
11. Eccles D.M., Evans D.G., Mackay J., Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. UK Cancer Family Study Group (UKCFSG). J Med Genet, 37:203-209, 2000
12. Ferlay J., Parkin D.M., Steliarova-Foucher E., Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer, 46(4):765-778, 2010
13. Fletcher O., Houlston R.S.,. Architecture of inherited susceptibility to common cancer. Nat Rev Cancer, 10(5):353-361, 2010
14. Ford D., Easton D.F., Peto J., Estimates of the gene frequency of BRCA1 mutations and its contribution to breast and ovarian cancer incidence. Am J Hum Genet, 57:1457-1462, 1995
15. Hallowell N., Foster C., Eeles R., Ardern-Jones A., Murday V., Watson M., Balancing autonomy and responsibility: the ethics of generating and disclosing genetic information. J Med Ethics, 29:74-83, 2003
16. Honrado E., Benitez J., Palacios J., The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol, 18(10):1305-1320, 2005
17. King M.C., Marks J.H., Mandell J.B., for The New York Breast Cancer Study Group, Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2. Science, 302:643-646, 2003
18. Lacroix M., Nycum G., Godard B., Knoppers B.M., Should physicians warn patients' relatives of genetic risks? CMAJ, 178(5), 593-595, 2008
19. Laurie G.T., In defence of ignorance: genetic information and the right to not know. Eur J Health Law, 6:119-32, 1999
20. Mackay J., Szecsei C.M., Genetic counselling for hereditary predisposition to ovarian and breast cancer. Ann Oncol, 21 Suppl 7:vii334-vii338, 2010
21. Mazilu L., Niculescu Z., Suceveanu A.I., Suceveanu A.P., Tofolean D., Adam T., Ethical aspects of communications with cancer patients, Revista Românǎ de Bioeticǎ, 8(3):181-188, 2010
22. Miron L., Miron I., Marinca M., Ethical particularities and dilemmas of informed consent in pediatric oncology. Revista Românǎ de Bioeticǎ, 7(1):18-24, 2009
23. McClellan J., King M.C., Genetic heterogeneity in human disease. Cell., 141(2):210-217, 2010
24. Narod S.A., BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol., 7(2):702-707, 2010
25. Narod S.A., Foulkes W.D., BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer, 4(9):665-676, 2004
26. Narod S.A., Modifiers of risk of hereditary breast and ovarian cancer. Nature Rev. Cancer, 2(2):113-123, 2002
27. Negurǎ L., Carasevici E., Negurǎ A., Uhrhammer N., Bignon Y.-J., Identification of a recurrent BRCA1 mutation in two breast/ovarian cancer predisposition families with distinct phenotypes, by allele-specific multiplex-PCR. Romanian Review of Laboratory Medicine, 18(2), 53-61, 2010
28. Negurǎ L., Uhrhammer N., Negurǎ A., Artenie V., CaraseviciE., Bignon Y.-J., Complete BRCA mutation screening and haplotype characterization within breast and ovarian cancer predisposition families in North-Eastern Romanian population. Familial Cancer, 9(4):519-523, 2010
29. Nycum G., Avard D., Knoppers B.M., Factors influencing intrafamilial communication of hereditary breast and ovarian cancer genetic information. European Journal of Human Genetics, 17:872-880, 2009
30. Rebbeck T.R., Lynch H.T., Neuhausen S.L., Narod S.A., Van't Veer L., Garber J.E. et al., Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New Eng. J. Med., 346:1616-1622, 2002
31. Richards M.P.M., How distinctive is genetic information? Studies in History and Philosophy of Biological and Biomedical Sciences, 32:663-687, 2001
32. Romanian Cancer League (http://www.romaniancancerleague.org/en/index.php).
33. Simon R., Zhang X., On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations. Int J Cancer, 122(8):1916-1917, 2008
34. Skene L., Patients' rights or family responsibilities? Med Law Rev, 6:1-41, 1998
35. Stângǎ O.A., Antonesi I.M., Toma A.I., Acknowledgment of the informed consent concept by human subjects actively involved in clinical research trials. Revista Românǎ de Bioeticǎ, 7(3):28-37, 2009
36. Sun C.C., Ramirez P. T, Bodurka D.C., Quality of Life for Patients With Epithelial Ovarian Cancer. Nat Clin Pract Oncol, 4(1):18-29, 2007
37. Thurlimann B. et al. (Breast International Group (BIG) 1-98 collaborative group, A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med, 353(26):2747-2757, 2005
38. Tischkowitz M., Mackay J., Inherited predisposition to cancer. In Cavalli F., Hansen H., Kaye S. (eds): Textbook of Medical Oncology, 3rd edition. London: Martin Dunitz, 413-426, 2004
39. Walsh T., King M.C., Ten genes for inherited breast cancer. Cancer Cell., 11(2):103-105, 2007
40. WHOSIS-World Health Organization Statistical Information System (http://www.who.int/whosis/en/).